{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.2155","upperLimit":"2.3982","value":"1.4783"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"15"}],"units":"Participants"}],"description":"Time from registration to the earliest of progressive disease, alternative treatment for myeloma, or death due to any cause, assessed up to 1 year. The distribution of failure-free survival will be estimated using the method of Kaplan-Meier.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive 650 mg Acetaminophen and 50 mg Benadryl orally 30 minutes prior to MV-NIS then receive MV-NIS IV over 1 hour on day 1.","id":"OG000","title":"Phase II (Acetaminophen + Benadryl + MV-NIS)"}],"paramType":"MEDIAN","populationDescription":"Phase II specified secondary endpoint will only include Phase II patients. Phase II Cohort A and Phase II Cohort B were combined for this analysis due to accrual terminating early in Cohort B.","reportingStatus":"POSTED","timeFrame":"Time from registration to the earliest of progressive disease, alternative treatment for myeloma, or death due to any cause, assessed up to 1 year","title":"Failure-free Survival (Phase II)","type":"SECONDARY","unitOfMeasure":"months"}